Close this search box.

PPP Specialist Series

Realising a pharmacy-led transformation of health and care

The Medicines and Pharmacy Programme in 2024 aims to shine a light upon how exactly the value of pharmacy can be maximised in conjunction with each of the four pillars of primary care and wider community services.

Medicines and Pharmacy Programme 2024

It is the strong belief of our existing medicines and pharmacy network that doing so will help enable integrated care systems (ICSs) to deliver upon the key objectives of integrated care, such as population health management and the reduction of health inequalities. 

In 2023, Public Policy Projects’ (PPP) Medicines and Pharmacy Programme highlighted the possibility of a pharmacy-led transformation of UK health and care. The Driving true value from medicines and pharmacy report found that pharmacy has the potential to become a system-wide strategic asset, with the potential to bring substantial value to integrated care delivery .

Insights generated from last year’s series of roundtables were accepted as evidence in the Health and Social Care Select Committee’s pharmacy inquiry. However, last year’s work also identified several barriers preventing pharmacy from becoming truly integrated with the wider primary care sector, including contractual, digital, and workforce limitations.  

In 2024, the Medicines and Pharmacy Programme will consist of four roundtables exploring the practicalities and opportunities for a pharmacy-led transformation of UK health and care. Across the roundtables, we will be exploring how pharmacy can be better integrated with the wider primary care sector, the relationship between effective medicine optimisation strategies and population health management, how differing levels of access to medicines across ICSs are contributing to health inequality and how this can be overcome.

The programme consists of:

  • Four virtual, 90-minute, invitation-only roundtables (February – May 2024)
  • Policy and insights reports capturing the recommendations from the programme.

Programme Chair: Yousaf Ahmad

The Chair of the PPP’s Medicines and Pharmacy Programme in 2024 is Yousaf Ahmad, Chief Pharmacist and Director of Medicines Optimisation at Frimley ICB. Building on the policy insights generated in 2023, Yousaf will be exploring how effective medicines optimisation strategies can be developed and leveraged to contribute to population health management and the reduction of health inequalities within ICSs.

Upcoming events 2024

Medicines and Pharmacy Programme 2024

All PPP events are free for the Public Sector including NHS Organisations, Local Authorities, academics, researchers, not-for-profit and third sector providers and charitable sectors. A limited number of Private Sector Tickets (suppliers) are available at £499.99 per ticket.

Our Medicines and Pharmacy network includes:

  • Chief Pharmacists 
  • Pharmacists
  • Pharmacy Technicians
  • Clinical Pharmacists
  • GPs
  • PCN Clinical Directors 
  • LPC Officers 
  • ICS Contract Managers
  • Non-Community Pharmacy Managers 
  • Directors of Medicines Governance 
  • PCN Lead Pharmacists
  • PCN Leaders
  • ICS Medicines Leaders
  • Regional Community Pharmacy Leaders
  • Pharmacy Consultants
  • Community Pharmacy Leads
  • Directors of Medicines and Clinical Policies

For more information about attending the roundtables, or partnering with PPP’s 2024 Medicines and Pharmacy Programme, contact Samantha Semmeling, Policy Analyst, or Lee Davies, Director of Strategy & Partnerships,

Related content:

Be a Partner for the Medicines and Pharmacy Programme 2024

We are proud to announce Spirit Health, Optum and Bayer as sponsors for this programme. 

Various levels of Partner opportunities exist for PPP’s Medicines and Pharmacy Programme 2024. For more information contact Lee Davies on

*Bayer has provided sponsorship funding for this series and has played a role in shaping the topic of this report, as well as contributing to the discussion. No speakers or contributors have received honoraria for their participation in this roundtable. Public Policy Projects has maintained complete editorial control, with Bayer reviewing this material in accordance with the relevant industry Code.

Scroll to Top